Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.
Authors: Morgan TR,  Lambrecht RW,  Bonkovsky HL,  Chung RT,  Naishadham D,  Sterling RK,  Fontana RJ,  Lee WM,  Ghany MG,  Wright EC,  O'Brien TR,  HALT-C Trial Group
Journal: J Hepatol
Date: 2008 Oct
Branches: EBP
PubMed ID: 18619701
PMC ID: PMC3903339
Abstract: BACKGROUND/AIMS: Certain host genetic polymorphisms reportedly affect the likelihood of a sustained virological response (SVR) to interferon treatment in subjects infected with hepatitis C virus (HCV). As part of the HALT-C trial we evaluated genetic associations among patients infected with HCV genotype 1 who had failed previous interferon treatment. METHODS: SVR was determined 24 weeks after completing treatment with pegylated interferon alfa-2a and ribavirin. Eight single nucleotide polymorphisms (SNPs) were selected on the basis of previously reported associations with treatment response. Genotypes were assessed by polymerase chain reaction-based assays. The percentage of patients who achieved SVR was determined for each genotype and for an IL10 promoter diplotype. RESULTS: Among 637 non-Hispanic Caucasian patients there were no significant associations between genotype for any individual SNP (IL10-1082, IL10-592, TNF-308, TNF-238, TGFB1 codon 25, CCL2-2518, EPHX1 codon 113 and AGT-6) and SVR, but SVR was more common among the patients who were homozygous for the ACC IL10 promoter diplotype (adjusted odds ratio, 3.24; 95% confidence interval, 1.33-7.78; p=0.001). CONCLUSIONS: Among non-Hispanic Caucasian patients treated with peginterferon and ribavirin after failing previous treatment with interferon, homozygosity for the ACC IL10 promoter diplotype was associated with SVR.